ストックスクリーナーアプリを入手
1.82
2.67%
-0.05
前日終値:
$1.87
開ける：
$1.88
24時間の取引高:
1.43M
Relative Volume:
0.58
時価総額：
$633.33M
収益：
-
当期純損益:
$-75.80M
株価収益率:
-5.20
EPS:
-0.35
ネットキャッシュフロー:
$-68.07M
1週間 パフォーマンス:
-3.70%
1か月 パフォーマンス:
-7.61%
6か月 パフォーマンス:
-23.85%
1年 パフォーマンス:
-50.00%
1日の値動き範囲:
$1.80
$1.885
1週間の範囲:
$1.80
$2.04
52週間の値動き範囲:
$1.71
$3.97
Nuvation Bio Inc Stock (NUVB) Company Profile
名前
Nuvation Bio Inc
セクター
電話
(415) 754-3517
住所
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
NUVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
1.82 | 633.33M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-27 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-26 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-04-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | 開始されました | BMO Capital Markets | Outperform |
| 2021-03-08 | 開始されました | BTIG Research | Buy |
| 2021-03-08 | 開始されました | Cowen | Outperform |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Nuvation Bio Inc (NUVB) 最新ニュース
Wedbush Reaffirms “Outperform” Rating for Nuvation Bio (NYSE:NUVB) - Defense World
Nuvation Bio Inc (NYSE: NUVB) Has Great Upside Potential - Stocks Register
Nuvation Bio Inc. (NYSE:NUVB) Stock Position Boosted by Charles Schwab Investment Management Inc. - Defense World
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025 - BioSpace
Breakthrough Cancer Drug Data: How Taletrectinib Targets Resistant Lung Cancer - StockTitan
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025 - BioSpace
Nuvation Bio Enters Supply Agreement With Asymchem For Taletrectinib - Marketscreener.com
Insider Stock Buying Reaches US$720.1k On Nuvation Bio - Yahoo Finance
Breakthrough Lung Cancer Treatment Comparison: Taletrectinib Shows Head-to-Head Data vs Standard Therapy - StockTitan
Bank of New York Mellon Corp Buys 14,203 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Sees Unusually High Options Volume (NYSE:NUVB) - Defense World
Nuvation Bio Inc (NYSE: NUVB) Is The Number One Stock Currently Moving. - Stocks Register
Is Nuvation Bio Inc. (NYSE:NUVB) the Most Oversold Penny Stocks to Buy According to Analysts? - Insider Monkey
Arizona State Retirement System Grows Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Analysts Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $8.33 - Defense World
Nuvation Bio Inc (NUVB): Be Patient, You Will Learn - Stocks Register
Jones Trading Begins Coverage on Nuvation Bio (NYSE:NUVB) - Defense World
Q1 EPS Estimates for Nuvation Bio Decreased by HC Wainwright - Defense World
Jones Trading Initiates Coverage of Nuvation Bio (NUVB) with Buy Recommendation - Nasdaq
Nuvation Bio Positioned for Growth with Key Therapeutics and Strategic Leadership - TipRanks
Jones Trading sets $10 target for Nuvation Bio stock with Buy rating - Investing.com Australia
Jones Trading sets $10 target for Nuvation Bio stock with Buy rating By Investing.com - Investing.com South Africa
Nuvation Bio initiated with a Buy at JonesResearch - TipRanks
Nuvation Bio (NYSE:NUVB) Shares Gap Down Following Analyst Downgrade - Defense World
Nuvation Bio (NYSE:NUVB) Price Target Cut to $10.00 by Analysts at HC Wainwright - Defense World
Nuvation Bio stock price target cut to $10 by H.C. Wainwright - Investing.com Canada
Nuvation Bio (NYSE:NUVB) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Nuvation Bio Inc (NUVB) expanding its growth trajectory ahead - SETE News
Q1 Earnings Estimate for Nuvation Bio Issued By Wedbush - Defense World
Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts - Insider Monkey
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact L - GuruFocus.com
Nuvation Bio Reports Transformative Year in 2024 - TipRanks
12 Best NYSE Penny Stocks to Buy According to Analysts - Insider Monkey
Wedbush Comments on Nuvation Bio’s Q3 Earnings (NYSE:NUVB) - Defense World
Nuvation Bio Positioned for Growth: Buy Rating Affirmed on Strategic Moves and Promising Drug Pipeline - TipRanks
Nuvation Bio Inc Files For Mixed Shelf, Size Not Disclosed -March 06, 2025 at 05:35 pm EST - Marketscreener.com
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Nuvation Bio reports Q4 EPS (15c), two estimates (12c) - TipRanks
Nuvation Bio Inc. SEC 10-K Report - TradingView
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - WICZ
Nuvation Bio Inc (NYSE: NUVB) Stock Is A Good Option To Consider - Stocks Register
Nuvation Bio Enters Supply Agreement With Asymchem Laboratories -March 05, 2025 at 05:14 pm EST - Marketscreener.com
Nuvation Bio scoops US$250M financing to launch promising lung cancer therapeutic - Mugglehead
Nuvation Bio secures $250m for taletrectinib commercialisation - Yahoo Finance
Nuvation Bio (NYSE:NUVB) Given Outperform Rating at Wedbush - Defense World
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners - BioSpace
Nuvation Bio secures up to $250M from Sagard Healthcare Partners; shares rise - MSN
New York's Nuvation Bio Nets $250M to Launch Lung Cancer Game-Changer - Hoodline
Nuvation Bio: Up To $250 Million In Non-Dilutive Financings Secured - Pulse 2.0
Midtown biotech raises $250M to bring lung cancer therapy to market - Crain's New York Business
Nuvation Bio Inc (NUVB) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):